Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

X-linked hypophosphatemia (XLH) causes significant burden in pediatric patients in spite of maintained treatment with phosphate supplements and vitamin D derivatives. Administration of burosumab has shown promising results in clinical trial but studies assessing its effect in the everyday practice a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín Ramos, Silvia, Gil-Calvo, Marta, Roldán, Virginia, Castellano Martínez, Ana, Santos, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040476/
https://www.ncbi.nlm.nih.gov/pubmed/32133333
http://dx.doi.org/10.3389/fped.2020.00048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040476/
https://www.ncbi.nlm.nih.gov/pubmed/32133333
http://dx.doi.org/10.3389/fped.2020.00048

Ejemplares similares